B Asselain1, J-R Barrière2, C Clarot3, J-P Vabre4, B Gentil Le Pecq5, Y Duval6, P Thomas7, D Herman8, M Grivaux9, D Debieuvre10. 1. Service d'oncologie médicale, hôpital Hôtel-Dieu, 1, place du Parvis de Notre Dame, 75004 Paris, France. Electronic address: b.asselain@gmail.com. 2. Service de pneumologie, centre hospitalier général, 83300 Draguignan, France. Electronic address: jean-renaud.barriere@ch-draguignan.fr. 3. Service de pneumologie, centre hospitalier, 80143 Abbeville, France. Electronic address: clarot.caroline@ch-abbeville.fr. 4. Service de pneumologie, centre hospitalier, 65107 Lourdes, France. Electronic address: jvabre@ch-lourdes.fr. 5. Service de pneumologie, centre hospitalier Pierre Oudot, 38317 Bourgoin Jallieu, France. Electronic address: bgentil@ch-bourgoin.fr. 6. Service de pneumologie, centre hospitalier, 06400 Cannes, France. Electronic address: y.duval@ch-cannes.fr. 7. Service de pneumologie, Site de Gap, centre hospitalier intercommunal des Alpes du Sud, 5007 Gap, France. Electronic address: pascal.thomas@chicas-gap.fr. 8. Service de pneumologie, centre hospitalier, hôpital Pierre Beregovoy, 58000 Nevers, France. Electronic address: dominique.herman@ch-nevers.fr. 9. Service de pneumologie, hôpital de Meaux, 6-8, rue Saint Fiacre, BP 218, 77104 Meaux cedex, France. Electronic address: michel.grivaux@wanadoo.fr. 10. Service de pneumologie, groupe hospitalier régional Mulhouse-Sud Alsace (GHRMSA), hôpital Emile Muller, 20, rue du Dr Laënnec, BP 1370, 68070 Mulhouse, France. Electronic address: debieuvred@ghrmsa.fr.
Abstract
BACKGROUND: Patients with metastatic non-small-cell lung cancer (NSCLC) who survive more than 2 years are considered long-term survivors (LTSs). The present study examined factors associated with long-term survival and collected information for future comparison. METHODS: Clinical, molecular, and therapeutic data were collected from patients followed for primary stage IV (7th TNM classification) NSCLC within 2 years from diagnosis in the respiratory medicine departments of 53 French non-teaching hospitals. LTS and non-LTS records were compared. Factors associated with long-term survival were examined by univariate and multivariate analyses using logistic regression models. RESULTS: Vital status at least 2 years after diagnosis was known for 1977 stage IV NSCLC patients; 220 (11.1%) were LTSs. On multivariate analysis, independent positive factors comprised: TTF-1(+) immunochemistry, EGFR-mutation, surgery, rescue radiotherapy, and targeted therapy. Independent negative factors comprised: prediagnosis weight loss>5kg, ECOG performance status>1, and primary radiotherapy. CONCLUSIONS: Molecular biology and targeted therapy were decisive for long-term survival. With their development and their widespread implementation in clinical practice, the percentage of LTSs is expected to grow. Factors determining long-term survival found in this study should be taken into account when considering treatment options for patients with stage IV NSCLC.
BACKGROUND:Patients with metastatic non-small-cell lung cancer (NSCLC) who survive more than 2 years are considered long-term survivors (LTSs). The present study examined factors associated with long-term survival and collected information for future comparison. METHODS: Clinical, molecular, and therapeutic data were collected from patients followed for primary stage IV (7th TNM classification) NSCLC within 2 years from diagnosis in the respiratory medicine departments of 53 French non-teaching hospitals. LTS and non-LTS records were compared. Factors associated with long-term survival were examined by univariate and multivariate analyses using logistic regression models. RESULTS: Vital status at least 2 years after diagnosis was known for 1977 stage IV NSCLCpatients; 220 (11.1%) were LTSs. On multivariate analysis, independent positive factors comprised: TTF-1(+) immunochemistry, EGFR-mutation, surgery, rescue radiotherapy, and targeted therapy. Independent negative factors comprised: prediagnosis weight loss>5kg, ECOG performance status>1, and primary radiotherapy. CONCLUSIONS: Molecular biology and targeted therapy were decisive for long-term survival. With their development and their widespread implementation in clinical practice, the percentage of LTSs is expected to grow. Factors determining long-term survival found in this study should be taken into account when considering treatment options for patients with stage IV NSCLC.
Authors: Paola Anna Jablonska; Joaquim Bosch-Barrera; Diego Serrano; Manuel Valiente; Alfonso Calvo; Javier Aristu Journal: Cancers (Basel) Date: 2021-04-29 Impact factor: 6.639
Authors: Laura Elena Pineda Lancheros; Cristina Pérez Ramírez; Almudena Sánchez Martín; José María Gálvez Navas; Fernando Martínez Martínez; María Del Carmen Ramírez Tortosa; Alberto Jiménez Morales Journal: Nutrients Date: 2021-10-25 Impact factor: 5.717
Authors: Borys Hrinczenko; Nicholas Iannotti; Sanjay Goel; David Spigel; Howard Safran; Matthew H Taylor; Jaafar Bennouna; Deborah J Wong; Karen Kelly; Claire Verschraegen; Marcis Bajars; Juliane Manitz; Mary Ruisi; James L Gulley Journal: Future Oncol Date: 2022-02-11 Impact factor: 3.674